Immunofluorescent staining of the BC marker KRT5 demonstrated no significant difference in positive cells between untreated, siRNA control and KRAS siRNA treated cells (75.1% untreated vs 71.0% siRNA control and 74.5% siRNA KRAS; Fig. 3a). The gene discussed is KRAS; the disease is breast cancer.